As a greater majority of NSCLC has ER-a expression, these new class of endocrine therapies in breast cancer focusing on ESR1 mutations may hold promise in future studies in HR+ NSCLC (57).Thus, additional clinical trials with more selective inclusion parameters and investigation of new TKIs and estrogen modulator combinations should be investigated in HR+ NSCLC. Here, ESR1 is linked to breast carcinoma.